Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

por Confavreux, Christian, Li, David K, Freedman, Mark S, Truffinet, Philippe, Benzerdjeb, Hadj, Wang, Dazhe, Bar-Or, Amit, Traboulsee, Anthony L, Reiman, Lucy E, O’Connor, Paul W
Publicado 2012